CLAIM AMENDMENTS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the Claims:

Claims 1-4 (**cancelled**).

Claim 5 (**currently amended**): A compound ~~according to claim 1~~ of the formula IIb:



(IIb)

wherein:

M is -CH- or -N-;

nc is 0, 1 or 2;

R^{2c} is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;

R^{2d} is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;

R^{2a} and R^{2b} are each independently selected from hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl, $-NR^{3a}R^{4a}$ (wherein R^{3a} and R^{4a}, which may be the same or different, each represents hydrogen or C_{1-3}alkyl), and Q^1X^1

wherein Q^1 is selected from one of the following groups:

1) C_{1-4}alkyl-Q^{13}-C(O)-C_{1-4}alkyl-Q^{14} wherein Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,


and


wherein Q^{14} is linked to C_{1-6}alkanoyl through a nitrogen atom;

2) Q^2 (wherein Q^2 is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,


and


which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C_{2-4}alkanoylC_{1-3}alkyl and optionally bears a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, C_{2-4}alkanoylC_{1-3}alkyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl)); and

3) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein);

and X^1 is O~~are as defined in claim 1~~;

and additionally wherein any C_{1-5}alkyl group in Q^1X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino;

Z^a is -O- or -S-;

with the proviso that at least one of R^{2a} and R^{2b} is Q^1X^1 wherein Q^1 and X^1 are as defined herein ~~in claim 1~~;

or a salt thereof.

Claim 6 (**currently amended**): A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 ~~is -O-~~ and Q^1 are as defined in claim 5.~~is selected from one of the following groups:~~

~~1) C_{1-4}alkyl-Q^{13}-C(O)-C_{1-4}alkyl-Q^{14} wherein Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,~~



and

~~wherein Q^{14} is linked to C_{1-6}alkanoyl through a nitrogen atom;~~

~~2) Q^2 (wherein Q^2 is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,~~



and

~~which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C_{2-4}alkanoylC_{1-3}alkyl and optionally bears a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, C_{2-4}alkanoylC_{1-3}alkyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-~~

~~$_4$alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl));~~

~~3) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein);~~

~~4) C_{1-4}alkylW^2C_{1-4}alkylQ^2 (wherein W^2 is as defined in claim 1 and Q^2 is as defined herein);~~

~~5) C_{1-4}alkylQ^{15}(C_{1-4}alkyl)$_j$(W^2)$_k$$Q^{16}$ (wherein W^2 is as defined in claim 1, j is 0 or 1, k is 0 or 1, and Q^{15} and Q^{16} are each independently selected from a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,~~



~~and~~

~~;~~

~~which heterocyclic group may bear either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, C_{2-4}alkanoylC_{1-3}alkyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the proviso one or both of Q^{15} and Q^{16} must be a 5-6-membered heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C_{2-4}alkanoylC_{1-3}alkyl and optionally bears 1 or 2 further~~

~~substituents selected from those defined herein);~~

~~6) C_{1-4}alkyl$Q^{15}$$C_{1-4}$alkanoyl$Q^{16n}$ wherein Q^{15} is as defined herein and Q^{16n} is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl.~~



and

~~wherein Q^{16n} is linked to C_{1-6}alkanoyl through a nitrogen atom and wherein Q^{16n} bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, C_{2-4}alkanoylC_{1-3}alkyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl); with the proviso that one or both of Q^{15} and Q^{16n} must be a 5-6-membered heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C_{2-4}alkanoylC_{1-3}alkyl and optionally bears 1 or 2 further substituents selected from those defined herein;~~

~~and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in Q^1X^1 which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino).~~

Claim 7 (**original**): A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 is

C_{1-4}alkyl-Q^{13}-C(O)-C_{1-4}alkyl-Q^{14} wherein Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,


and

,

wherein Q^{14} is linked to C_{1-6}alkanoyl through a nitrogen atom.

Claim 8 (**original**): A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 is selected from one of the following groups:

1) Q^2 (wherein Q^2 is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,


and

,

which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears one substituent selected from C_{2-4}alkanoylC_{1-3}alkyl; and

2) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein).

Claim 9 (**original**): A compound according to claim 7 or claim 8 wherein R^{2a} is methoxy.

Claim 10 (**currently amended**): A compound according to claim 5 ~~claim 1~~ selected from:

7-{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]quinazoline,

7-{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]quinazoline,

7-{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-

yl)oxy]quinazoline,

6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,

6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,

6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,

6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

4-[(2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]quinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-{2-[4-(pyrrolidin-1-ylacetyl)piperazin-1-yl]ethoxy}quinazoline,

7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]quinazoline,

7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline, and

7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

and salts ~~or a salt~~ thereof.

Claim 11 (**currently amended**): A compound according to claim 5 ~~claim 1~~ selected from:

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline, and

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

and salts ~~or a salt~~ thereof.

Claim 12 (**currently amended**): A compound according to any one of claims 5, 10 and 11 ~~the preceding claims~~ in the form of a pharmaceutically acceptable salt.

Claim 13 (**currently amended; withdrawn**): A process for the preparation of a compound according to claim 5 ~~claim 1~~ of the formula I or salt thereof which comprises:

(a) the reaction of a compound of the formula III:



(III)

(wherein R^2 and m are as defined in claim 5 ~~claim 1~~ and L^1 is a displaceable moiety), with a compound of the formula IV:



(IV)

(wherein ring C, R^1, Z and n are as defined in claim 5 ~~claim 1~~) optionally followed by the addition of a substituent on a heterocyclic ring of R^1 or R^2;

(b) for compounds of formula I and salts thereof wherein at least one R^2 is R^5X^1 or Q^1X^1 wherein R^5 and Q^1 are as defined in claim 5 ~~claim 1~~, and X^1 is -O-, -S-, -OC(O)- or -NR^{10}- (wherein R^{10} independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) the reaction of a compound of the formula V:



(V)

(wherein ring C, Z, R^1, R^2 and n are as defined in claim 5 ~~claim 1~~ and X^1 is as defined in this section and s is an integer from 0 to 2) with one of the compounds of the formulae VIa-b:

$$R^5\text{-}L^1 \qquad \text{(VIa)}$$

$$Q^1\text{-}L^1 \qquad \text{(VIb)}$$

(wherein R^5 and Q^1 are as defined in claim 5 ~~claim 1~~ and L^1 is as defined herein);

(c) for compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 or Q^1X^1 wherein R^5 and Q^1 are as defined in claim 5 ~~claim 1~~, and X^1 is -O-, -S-, -OC(O)- or -NR^{10}- (wherein R^{10} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) the reaction of a compound

of the formula VII:



(VII)

with one of the compounds of the formulae VIIIa-b:

R^5-X^1-H (VIIIa)

Q^1-X^1-H (VIIIb)

(wherein R^1, R^2, R^5, Q^1, ring C, Z and n are as defined in claim 5~~-claim 1~~, L^1 and s are as defined herein and X^1 is as defined in this section;

(d) for compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 or Q^1X^1 wherein X^1 is as defined in claim 5~~-claim 1~~, R^5 is C_{1-5}alkylR^{113}, wherein R^{113} is selected from one of the following nine groups:

1) $X^{19}C_{1-3}$alkyl (wherein X^{19} represents -O-, -S-, -SO_2-, -NR^{114}C(O)- or –$NR^{115}SO_2$- (wherein R^{114} and R^{115} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

2) $NR^{116}R^{117}$ (wherein R^{116} and R^{117} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

3) $X^{20}C_{1-5}$alkylX^5R^{22} (wherein X^{20} represents -O-, -S-, -SO_2-, -NR^{118}C(O)-, -$NR^{119}SO_2$- or –NR^{120}- (wherein R^{118}, R^{119}, and R^{120} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and X^5 and R^{22} are as defined in claim 5~~-claim 1~~);

4) R^{28} (wherein R^{28} is as defined in claim 5~~-claim 1~~);

5) $X^{21}R^{29}$ (wherein X^{21} represents -O-, -S-, -SO_2-, -NR^{121}C(O)-, -$NR^{122}SO_2$-, or –NR^{123}- (wherein R^{121}, R^{122}, and R^{123} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined in claim 5~~-claim 1~~);

6) $X^{22}C_{1-3}alkylR^{29}$ (wherein X^{22} represents -O-, -S-, $-SO_2-$, $-NR^{124}C(O)-$, $-NR^{125}SO_2-$ or $-NR^{126}-$ (wherein R^{124}, R^{125} and R^{126} each independently represents hydrogen, C_{1-3}alkyl or $C_{1-3}alkoxyC_{2-3}$alkyl) and R^{29} is as defined in claim 5 ~~claim 1~~);

7) R^{29} (wherein R^{29} is as defined in claim 5 ~~claim 1~~);

8) $X^{22}C_{1-4}alkylR^{28}$ (wherein X^{22} and R^{28} are as defined in claim 5 ~~claim 1~~); and

9) $R^{54}(C_{1-4}alkyl)_q(X^9)_rR^{55}$ (wherein q, r, X^9, R^{54} and R^{55} are as defined in claim 5 ~~claim 1~~);

Q^1 is $C_{1-5}alkylQ^{27}$ wherein Q^{27} is selected from one of the following six groups:

1) Q^{13}-C(O)-$C_{1-4}alkylQ^{14}$ (wherein Q^{13} and Q^{14} are as defined in claim 5 ~~claim 1~~);

2) W^1Q^2 (wherein W^1 and Q^2 are as defined in claim 5 ~~claim 1~~);

3) Q^2 (wherein Q^2 is as defined in claim 5 ~~claim 1~~);

4) $W^2C_{1-4}alkylQ^2$ (wherein W^2 and Q^2 are as defined in claim 5 ~~claim 1~~);

5) $Q^{15}(C_{1-4}alkyl)_j(W^2)_kQ^{16}$ (wherein W^2, j, k, Q^{15} and Q^{16} are as defined in claim 5 ~~claim 1~~);

6) $Q^{15}C_{1-4}alkanoylQ^{16n}$ (wherein Q^{15} and Q^{16n} are as defined in claim 5 ~~claim 1~~);

the reaction of a compound of the formula IX:



(IX)

(wherein X^1, R^1, R^2, ring C, Z and n are as defined in claim 5 ~~claim 1~~ and L^1 and s are as defined herein) with one of the compounds of the formulae Xa-b:

R^{113}-H (Xa)

Q^{27}-H (Xb)

(wherein R^{113} and Q^{27} are as defined herein) optionally followed by the addition of a substituent on a heterocyclic ring of R^1 or R^2;

and when a salt of a compound of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.

Claim 14 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula IIb ~~formula I~~ as defined in claim 5 ~~claim 1~~ or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

Claim 15 (**cancelled**)

Claim 16 (**currently amended; withdrawn**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula IIb ~~formula I~~ as defined in claim 5 ~~claim 1~~ or a pharmaceutically acceptable salt thereof.